Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine
ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, United States · Tagged with: Anthrax vaccines, Clinical trial, Emergent BioSolutions, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services
Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians
ROCKVILLE, Md., Jul 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE:EBS) is hosting “Bioterrorism Prevention, Preparedness and Response,” a forum organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA) to raise global awareness of the importance of biopreparedness. The visiting delegation [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, U.S. Food and Drug Administration, United States, Washington · Tagged with: Anthrax vaccines, Emergent BioSolutions, Food and Drug Administration, NATO, United States, United States Department of Health and Human Services
Bad News Clouds Two Bio Defense Stocks
Written by Staff and Wire Reports
Tuesday, 08 December 2009 01:28
Key news developments will affect shares of these two companies who help meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons.
The two companies which waited until late after hours on Monday to announce [...]
In: Chief Executive Officer, Emergent Bioslutions, Federal government of the United States, Fuad El-Hibri, Strategic National Stockpile · Tagged with: Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, Federal government of the United States, Fuad El-Hibri, Project Bioshield Act, Strategic National Stockpile, United States, United States Department of Health and Human Services
Emergent Biosolutions Submits Proposal In Response To Hhs’ Rfp For Development And Procurement Of A Recombinant Protective Antigen Anthrax Vaccine
The company’s submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has submitted a proposal in response to a request for proposal (RFP) issued by the U.S. Department of Health and [...]
In: Uncategorized · Tagged with: Clinical trial, Infectious disease, rPA 102, Strategic National Stockpile, United States, United States Department of Health and Human Services, US Food and Drug Administration, US government
Emergent Biosolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate And Technology
Acquisition positions Emergent to offer the U.S. Government a domestic source for an advanced anthrax vaccine candidate to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed the acquisition of all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product [...]
In: Uncategorized · Tagged with: Clinical trial, Fort Detrick, Strategic National Stockpile, United States, United States Department of Health and Human Services, US Food and Drug Administration, US government, VaxGen